IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 20.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 612,672 shares of the company's stock after selling 155,783 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.75% of IDEXX Laboratories worth $309,534,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Chicago Partners Investment Group LLC raised its holdings in IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock valued at $340,000 after acquiring an additional 96 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of IDEXX Laboratories by 13.8% in the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock valued at $5,825,000 after purchasing an additional 1,453 shares during the last quarter. National Pension Service lifted its position in IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after buying an additional 12,647 shares in the last quarter. EFG Asset Management Americas Corp. grew its holdings in IDEXX Laboratories by 45.3% in the 2nd quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock valued at $6,201,000 after buying an additional 3,966 shares in the last quarter. Finally, Larson Financial Group LLC grew its holdings in IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after buying an additional 2,241 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now owns 905 shares of the company's stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Down 0.5 %

Shares of NASDAQ IDXX traded down $2.18 during trading on Monday, reaching $412.75. The stock had a trading volume of 388,198 shares, compared to its average volume of 512,553. The business's 50-day moving average price is $427.86 and its 200-day moving average price is $464.82. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The company has a market cap of $33.80 billion, a P/E ratio of 39.80, a PEG ratio of 3.94 and a beta of 1.37.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.53 earnings per share. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IDXX has been the topic of several recent research reports. Leerink Partners started coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. Piper Sandler reiterated a "neutral" rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a report on Thursday, October 10th. Finally, Barclays cut their target price on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $539.63.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.